Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AssigneesBristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
InventorsRichard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
Claims20
An antisense oligonucleotide (ASO) comprising the contiguous nucleotide sequence of AtTcctttacaccACAC (SEQ ID NO:
- 4), wherein the upper letter is beta-D-oxy-LNA and the lower letter is DNA.
Dependencies are inferred from the claim text.